0001209191-23-006279.txt : 20230202 0001209191-23-006279.hdr.sgml : 20230202 20230202172324 ACCESSION NUMBER: 0001209191-23-006279 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230201 FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harmon Cyrus CENTRAL INDEX KEY: 0001831410 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39712 FILM NUMBER: 23582349 MAIL ADDRESS: STREET 1: C/O OLEMA PHARMACEUTICALS, INC. STREET 2: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (415) 651-3316 MAIL ADDRESS: STREET 1: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-01 0 0001750284 Olema Pharmaceuticals, Inc. OLMA 0001831410 Harmon Cyrus C/O OLEMA PHARMACEUTICALS, INC. 512 2ND STREET, 4TH FLOOR SAN FRANCISCO CA 94107 1 1 0 0 Chief Research Officer Stock Option (Right to Buy) 4.87 2023-02-01 4 A 0 150000 0.00 A 2033-01-31 Common Stock 150000 150000 D 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ John B. Moriarty, Jr., Attorney-in-Fact 2023-02-02